ETF Holdings Breakdown of RGEN

Stock Name	Repligen Corporation
Ticker	RGEN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US7599161095
LEI	54930006QJ0T5AUO1E71

RGEN institutional holdings

The adjusted close for RGEN on 2025-11-11 was 153.44

The following institutional investment holdings of RGEN have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-11 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 37,557 USD 5,762,746 5.1% 153.44

2025-11-11 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 30,341 USD 4,655,523 5.1% 153.44

2025-11-11 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 63,908 USD 9,806,044 5.1% 153.44

2025-11-11 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 121 USD 18,566 5.1% 153.44

2025-11-11 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,966 6.3% USD 301,663 11.0% 153.44

2025-11-11 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 370 USD 56,773 5.1% 153.44

Total = 134,263 USD 20,601,315
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	37,557	USD 5,762,746 5.1%	153.44
2025-11-11	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	30,341	USD 4,655,523 5.1%	153.44
2025-11-11	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	63,908	USD 9,806,044 5.1%	153.44
2025-11-11	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	121	USD 18,566 5.1%	153.44
2025-11-11	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,966 6.3%	USD 301,663 11.0%	153.44
2025-11-11	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	370	USD 56,773 5.1%	153.44
Total =	134,263	USD 20,601,315

News associated with RGEN

Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Analysts: Repligen Corporation (NASDAQ:RGEN – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price […] - 2025-09-19 03:14:49
Repligen Corporation (NASDAQ:RGEN) Receives $169.45 Average Target Price from Analysts: Repligen Corporation (NASDAQ:RGEN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target […] - 2025-08-28 03:14:53
Rep. Lisa C. McClain Sells Off Shares of Repligen Corporation (NASDAQ:RGEN): Representative Lisa C. McClain (R-Michigan) recently sold shares of Repligen Corporation (NASDAQ:RGEN). In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Repligen stock on June 17th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account. Representative Lisa C. McClain also recently made […] - 2025-08-21 03:08:43
Swiss National Bank Sells 1,500 Shares of Repligen Corporation (NASDAQ:RGEN): Swiss National Bank decreased its position in Repligen Corporation (NASDAQ:RGEN – Free Report) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,200 shares of the biotechnology company’s stock after selling 1,500 shares during the quarter. Swiss […] - 2025-08-15 05:44:53
Repligen Corporation (NASDAQ:RGEN) Shares Acquired by PNC Financial Services Group Inc.: PNC Financial Services Group Inc. lifted its position in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 4.4% in the first quarter, Holdings Channel reports. The firm owned 3,632 shares of the biotechnology company’s stock after purchasing an additional 152 shares during the period. PNC Financial Services Group Inc.’s holdings in Repligen were worth […] - 2025-08-14 05:32:58
Wealthquest Corp Invests $264,000 in Repligen Corporation (NASDAQ:RGEN): Wealthquest Corp acquired a new position in Repligen Corporation (NASDAQ:RGEN – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,077 shares of the biotechnology company’s stock, valued at approximately $264,000. Other hedge funds have also recently bought and sold shares of the […] - 2025-08-01 04:44:56
Thornburg Investment Management Inc. Has $4.29 Million Position in Repligen Corporation (NASDAQ:RGEN): Thornburg Investment Management Inc. trimmed its stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 4.7% in the first quarter, Holdings Channel.com reports. The firm owned 33,720 shares of the biotechnology company’s stock after selling 1,646 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Repligen were worth $4,291,000 at the end […] - 2025-07-30 04:44:45
Repligen Corporation (NASDAQ:RGEN) Shares Bought by Signaturefd LLC: Signaturefd LLC raised its position in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 65.3% during the 1st quarter, Holdings Channel reports. The firm owned 324 shares of the biotechnology company’s stock after buying an additional 128 shares during the quarter. Signaturefd LLC’s holdings in Repligen were worth $41,000 as of its most recent […] - 2025-07-24 05:00:47
Ballentine Partners LLC Has $224,000 Stock Holdings in Repligen Corporation (NASDAQ:RGEN): Ballentine Partners LLC lessened its stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 6.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,759 shares of the biotechnology company’s stock after selling 120 shares during the period. […] - 2025-07-17 06:05:50
Allworth Financial LP Sells 733 Shares of Repligen Corporation (NASDAQ:RGEN): Allworth Financial LP reduced its position in Repligen Corporation (NASDAQ:RGEN – Free Report) by 47.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 809 shares of the biotechnology company’s stock after selling 733 shares during the quarter. Allworth Financial LP’s […] - 2025-07-17 05:25:12
Repligen Corporation (NASDAQ:RGEN) Shares Bought by State of Michigan Retirement System: State of Michigan Retirement System grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 0.8% in the 1st quarter, Holdings Channel reports. The fund owned 12,453 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the period. State of Michigan Retirement System’s holdings in Repligen were worth […] - 2025-07-15 06:28:23
DekaBank Deutsche Girozentrale Decreases Holdings in Repligen Corporation (NASDAQ:RGEN): DekaBank Deutsche Girozentrale trimmed its holdings in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 1.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,750 shares of the biotechnology company’s stock after selling 80 shares during the period. DekaBank Deutsche […] - 2025-07-14 05:34:50
Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Teacher Retirement System of Texas: Teacher Retirement System of Texas grew its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 61.7% during the 1st quarter, HoldingsChannel.com reports. The firm owned 15,811 shares of the biotechnology company’s stock after buying an additional 6,036 shares during the period. Teacher Retirement System of Texas’ holdings in Repligen were worth $2,012,000 at the […] - 2025-07-11 05:50:59
Repligen (NASDAQ:RGEN) Price Target Cut to $130.00 by Analysts at Evercore ISI: Repligen (NASDAQ:RGEN – Free Report) had its target price cut by Evercore ISI from $140.00 to $130.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an in-line rating on the biotechnology company’s stock. A number of other brokerages have also recently issued reports on RGEN. Wall Street Zen cut shares of Repligen […] - 2025-07-11 03:08:46
Principal Financial Group Inc. Boosts Holdings in Repligen Corporation (NASDAQ:RGEN): Principal Financial Group Inc. grew its position in Repligen Corporation (NASDAQ:RGEN – Free Report) by 55.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 186,715 shares of the biotechnology company’s stock after purchasing an additional 66,808 shares during the period. Principal Financial Group Inc.’s holdings in Repligen were worth $23,758,000 at the end […] - 2025-07-09 05:51:35
New York State Teachers Retirement System Has $6.49 Million Stake in Repligen Corporation (NASDAQ:RGEN): New York State Teachers Retirement System reduced its position in Repligen Corporation (NASDAQ:RGEN – Free Report) by 5.4% during the first quarter, HoldingsChannel reports. The firm owned 51,032 shares of the biotechnology company’s stock after selling 2,900 shares during the period. New York State Teachers Retirement System’s holdings in Repligen were worth $6,493,000 at the […] - 2025-07-06 06:14:54
Mirae Asset Global Investments Co. Ltd. Purchases 11,193 Shares of Repligen Corporation (NASDAQ:RGEN): Mirae Asset Global Investments Co. Ltd. boosted its position in Repligen Corporation (NASDAQ:RGEN – Free Report) by 60.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 29,822 shares of the biotechnology company’s stock after purchasing an additional 11,193 shares during the period. Mirae Asset Global Investments […] - 2025-07-02 06:04:50
Retirement Systems of Alabama Acquires 86 Shares of Repligen Corporation (NASDAQ:RGEN): Retirement Systems of Alabama boosted its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 0.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,418 shares of the biotechnology company’s stock after acquiring an additional 86 shares during the period. Retirement […] - 2025-06-24 05:32:52
Parallel Advisors LLC Reduces Holdings in Repligen Co. (NASDAQ:RGEN): Parallel Advisors LLC reduced its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 30.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 285 shares of the biotechnology company’s stock after selling 123 shares during the quarter. Parallel Advisors LLC’s holdings in Repligen were worth $36,000 at the end of the most recent quarter. […] - 2025-06-10 04:46:53
Squarepoint Ops LLC Sells 81,814 Shares of Repligen Co. (NASDAQ:RGEN): Squarepoint Ops LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 85.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,291 shares of the biotechnology company’s stock after selling 81,814 shares during the quarter. Squarepoint Ops LLC’s holdings in Repligen were worth $2,057,000 as of its most […] - 2025-05-29 05:52:48
ProShare Advisors LLC Has $351,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN): ProShare Advisors LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 7.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,438 shares of the biotechnology company’s stock after acquiring an additional 167 shares during the period. ProShare Advisors LLC’s […] - 2025-05-29 05:08:49
Tidal Investments LLC Decreases Stock Holdings in Repligen Co. (NASDAQ:RGEN): Tidal Investments LLC lowered its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 60.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,437 shares of the biotechnology company’s stock after selling 6,712 shares during the period. Tidal […] - 2025-05-28 05:52:53
Repligen Co. (NASDAQ:RGEN) Shares Sold by Bank of America Corp DE: Bank of America Corp DE decreased its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 36.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 277,947 shares of the biotechnology company’s stock after selling 158,404 shares during the period. Bank of America […] - 2025-05-16 06:38:55
Financial Survey: Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE): Repligen (NASDAQ:RGEN – Get Free Report) and Maze Therapeutics (NASDAQ:MAZE – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings. Analyst Recommendations This is a summary of recent recommendations […] - 2025-05-16 02:09:10
Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright: Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 38.04% from the stock’s previous close. […] - 2025-05-07 02:58:48
Repligen (NASDAQ:RGEN) Given New $190.00 Price Target at JPMorgan Chase & Co.: Repligen (NASDAQ:RGEN – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $200.00 to $190.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other reports. Wolfe Research raised shares of Repligen […] - 2025-04-30 05:32:52
Repligen (NASDAQ:RGEN) Upgraded by Wolfe Research to Outperform Rating: Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a peer perform rating to an outperform rating in a report published on Tuesday, Marketbeat.com reports. They currently have $160.00 price objective on the biotechnology company’s stock. A number of other research firms have also weighed in on RGEN. Royal Bank of Canada upped […] - 2025-04-30 05:32:47
StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”: Repligen (NASDAQ:RGEN – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research analysts have also recently commented on the company. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and […] - 2025-04-30 04:45:01
Legal & General Group Plc Lowers Stock Position in Repligen Co. (NASDAQ:RGEN): Legal & General Group Plc trimmed its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,904 shares of the biotechnology company’s stock after selling 5,698 shares during the quarter. Legal & General […] - 2025-04-17 05:57:10
Federated Hermes Inc. Lowers Holdings in Repligen Co. (NASDAQ:RGEN): Federated Hermes Inc. reduced its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 98.4% in the 4th quarter, Holdings Channel reports. The fund owned 5,266 shares of the biotechnology company’s stock after selling 316,555 shares during the period. Federated Hermes Inc.’s holdings in Repligen were worth $758,000 as of its most recent […] - 2025-04-16 05:50:56

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.